DRB (Synonyms: NSC 401575,Benzimidazole) |
| رقم الكتالوجGC17015 |
DRB هو نظير نيوكليوزيد يثبط العديد من كينازات مجال الكربوكسيل (CTD) بما في ذلك الكازين كيناز II و CDK. يحفز DRB موت الخلايا المبرمج المعتمد على p53 لخلايا سرطان القولون البشري دون إحداث إجهاد وراثي للخلايا السليمة.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 53-85-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
5, 6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) is a transcriptional elongation inhibitor.
Cyclin-dependent kinases (CDKs) belong to a family of protein kinases involved in regulating the cell cycle, transcription, mRNA processing, and the differentiation of nerve cells.[1] They are expressed in all known eukaryotes. With cyclin, CDK shows kinase activity. CDKs are serine-threonine kinases [1].
DRB inhibited the activity of several carboxyl-terminal domain (CTD) kinases including casein kinase II, Cdk7, Cdk8, and Cdk9 with the IC50 of 4-10 μM, ~20 μM, ~20 μM, and 3 μM) [2-5]. In HeLa cells, DRB (75 μM) inhibited 60-75% of nuclear heterogeneous RNA (hnRNA) synthesis. DRB (75 μM) reduced the appearance of labeled cytoplasmic poly(A)-containing messenger RNA (mRNA) by approximately 95%. DRB inhibited the initiation of hnRNA chains, but did not directly interfere with labeling of poly(A) [6]. DRB inhibited influenza virus multiplication in the chorioallantoic membrane in vitro [7]. DRB inhibited a HeLa protein kinase whihc phosphorylated an RNA polymerase II-derived peptide [8]. DRB can also inhibit HIV transcription (IC50 = ~4 μM) by targeting elongation enhanced by the HIV-encoded transactivator Tat.
References:
[1]. Zandomeni, R.O. Kinetics of inhibition by 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole on calf thymus casein kinase II. Biochemistry Journal 262, 469-473 (1989).
[2]. Yankulov, K.,Yamashita, K.,Roy, R., et al. The transcriptional elongation inhibitor 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase. The Journal of Biological Chemisty 270(41), 23922-23925 (1995).
[3]. Rickert, P.,Corden, J.L., and Lees, E. Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases. Oncogene 18, 1093-1102 (1999).
[4]. Schang, L.M. Cyclin-dependent kinases as cellular targets for antiviral drugs. Journal of Antimicrobial Chemotherapy 50, 779-792 (2002).
[5] Sehgal P B, Darnell J E, Tamm I. The inhibition of DRB (5, 6-dichloro-1-β-d-ribofuranosylbenzimidazole) of hnRNA and mRNA production in HeLa cells[J]. Cell, 1976, 9(3): 473-480.
[6] Tamm I, Tyrrell D A J. Influenza virus multiplication in the chorioallantoic membrane in vitro: kinetic aspects of inhibition by 5, 6-dichloro-1-β-D-ribofuranosylbenzimidazole[J]. The Journal of experimental medicine, 1954, 100(6): 541.
[7] Stevens A, Maupin M K. 5, 6-Dichloro-1-β-d-ribofuranosylbenzimidazole inhibits a HeLa protein kinase that phosphorylates an RNA polymerase II-derived peptide[J]. Biochemical and biophysical research communications, 1989, 159(2): 508-515.
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *